Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer

BACKGROUND: Despite the clinical success of vascular endothelial growth factor (VEGF) blockade in metastatic colorectal cancers (mCRC), resistance to anti-angiogenic drugs invariably develops. IL-8 and other cytokines have been implicated in development of resistance to anti-angiogenic therapy. Levo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Gastrointest Oncol
Hlavní autoři: Amin, Manik, Desai, Monica, Trinkaus, Kathryn, Brown, Amberly, Wang-Gillam, Andrea, Tan, Benjamin, Picus, Joel, Sorscher, Steven, Highkin, Maureen, Lears, Kim, Lockhart, Albert C.
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2019
Témata:
Clinical Trial
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534727/
https://ncbi.nlm.nih.gov/pubmed/31183190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.02.01
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky